摘要
目的研究二甲双胍治疗糖尿病高血脂的临床疗效。方法将我院2018年8月至2019年8月收治的90例糖尿病高血脂患者,按照随机数字表法分为两组均45例,对照组实施阿卡波糖和瑞舒伐他汀治疗,研究组在此基础上加用二甲双胍治疗,观察两组患者治疗前后血糖及血脂情况,并记录低血糖情况与血脂达标率。结果治疗前两组患者各项血糖之间无差异,治疗前各项血脂、低血糖发生率无差异(P>0.05),治疗后研究组血糖低于对照组,治疗后研究组血脂优于对照组,研究组血脂达标率93.33%高于对照组80.00%,差异有统计学意义(P<0.05)。结论对于糖尿病高血脂实施二甲双胍进行治疗,可有效改善患者血糖情况,并降低患者血脂水平,血脂达标率较高,低血糖发生率较低,值得应用。
Objective To investigate the clinical effect of metformin in the treatment of diabetes with hyperlipidemia Methods A A total of 90 patients with diabetes and hyperlipidemia who were admitted to our hospital from August 2018 to August 2019 were enrolled and divided into study group and control group using a random number table,with 45 patients in each group.The patients in the control group were given acarbose and rosuvastatin,and those in the study group were given metformin in addition to the treatment in the control group.The two groups were observed in terms of blood glucose,blood lipid levels,incidence of hypoglycemia,and rate of reaching the standard blood lipid levels before and after treatment.Results Before treatment,there were no significant differences in blood glucose,blood lipid levels,and incidence of hypoglycemia between the two groups(P>0.05).After treatment,compared with the control group,the study group had significantly lower blood glucose,significantly better blood lipid levels,and a significantly higher rate of reaching the standard blood lipid levels(93.33%vs 80.00%,P<0.05).Conclusion In patients with diabetes and hyperlipidemia,metformin can effectively improve blood glucose and reduce blood lipid levels,with a relatively high rate of reaching the standard blood lipid levels and a relatively low incidence of hypoglycemia.Therefore,it holds promise for clinical application.
作者
唐康
TANG Kang(Nanchong Central Hospital,Nanchong 637000,China)
出处
《心血管病防治知识（学术版）》
2020年第29期29-31,共3页
Prevention and Treatment of Cardiovascular Disease
关键词
二甲双胍
糖尿病
高血脂
Metformin
Diabetes
Hyperlipidemia
